The company has identified that inconsistencies in the cleaning process have led to low levels of a previous product being carried over into the Stresnil batch no PP1466, EXPIRY: 30-09-2019.
For more information about the recall, contact Matthew Edwards: elanco_orders@lilly.com or telephone: 01256 779519.
Kate Murphy and Mellora Sharman from VetCT, Mayank Seth and Rachel Miller from Stansted Veterinary Specialists and Andy Kent from Blaise Referrals have all signed up to get the new VetSurgeon.org email digest of questions posted on the site and will help when they can.
To get things started, any VetSurgeon.org member who posts a question about small animal medicine AND subscribes to the daily or weekly email digest (by logging in and clicking the red box on the homepage) before close of play on 15th August 2023 will go in the hat to win a bottle of Moet champagne.
VetSurgeon.org editor Arlo Guthrie said: "There are many reasons why this new Q&A community is better for professional clinical discussions than other forms of social media, but perhaps the most important is that when you ask a question, you’re not just helping yourself.
"Your question and any answers you receive go into an easily searchable knowledgebase of experience and opinion for the benefit of everyone in the veterinary profession.
"Beyond that, we don't use an algorithm to prioritise posts you are likely to react to, so we avoid the sort of echo chamber bias found on Facebook.
"Other social media also gives undeserved equivalence to all opinions, whereas we highlight those expressed by people with advanced qualifications and experience.
"Finally, VetSurgeon.org is now about one thing and one thing only, which is vets helping each other.
"That makes us much more focused.
"All in all, it means that VetSurgeon.org is where you'll get an authoritative answer."
General practitioners are also strongly encouraged to login and subscribe to the VetSurgeon.org Digest of questions, either daily or weekly.
Arlo added: "You'll get a daily or weekly list of veterinary questions asked by your peers.
"Some you'll want to know the answer to too.
"Some you may be able to help with.
"Answers are welcome not just from Specialists and referral practitioners, but also from general practitioners, industry members and academics."
Merck, part owner of Merial, has announced a merger with Intervet Schering-Plough.
However, rumours that Merck plans to sell its 50% stake in Merial and move forward with Intervet Schering Plough are incorrect, according to Merck spokespeople.
They'll have to start thinking about what to call themselves soon. Merial-Intervet-Schering-Plough is a bit of a mouthful.
Staffies were by far the most commonly stolen animal, accounting for 25.7% of all reported dogs thefts in the UK between 2017 and 2021.
Meanwhile, Devon and Cornwall had the highest number of pet thefts: 140.6 per 100,000 people.
Northumbria came second, with 61.5 pet thefts per 100,000 people, and Lancashire third (52.9 per 100,000).
On the other end of the scale, one breed that was less likely to be stolen was the pug (4.5%), although that's perhaps not surprising: after all, who'd want to steal an animal whose face you can't differentiate from its backside?
The safest animal in the country is probably an Akita (1.9%) living in Surrey (6.8 pet thefts per 100,000 people).
Full report: https://www.adt.co.uk/blog/the-adt-pet-theft-report
TVM says Emedog provides less wastage, provides easier dosing and is a solution designed specifically for veterinary use.
Simon Boulton MRCVS, Marketing Manager at TVM said: "The use of apomorphine in practice is a vital first-line response when emesis is required due to the ingestion of unwanted substances.
However, 86% of vets questioned thought that wastage was an issue with Apometic and many thought that dosing was difficult in very small animals due to tiny volumes. The new solution is Emedog. Practitioners must be aware that the dose of Emedog is different to that of Apometic and use accordingly."
TVM have provided a dosing guide as part of a changeover pack to aid in the transition. For a copy, contact your local TVM territory manager, email them via help@tvm-uk.com, download from www.tvm-uk.com or ring 01737 781416.
Cytopoint is an injectable monoclonal antibody therapy for dogs that targets and neutralises the cytokine IL-31, a mediator of allergic itch1.
Zoetis says the new claim was granted following a randomised, double-masked, multi-centred, placebo-controlled study which looked at Cytopoint’s efficacy and safety for the treatment of pruritus associated with allergic dermatitis in client-owned dogs. The study showed that Cytopoint significantly decreased pruritus, and improved skin lesions.2
Allison Henry, Product Manager Companion Animal Dermatology at Zoetis UK, says: "Allergic dermatitis is one of the most common skin conditions in dogs.3 The associated clinical signs – including scratching, hair loss and skin lesions – are disruptive for the dog, impacting their quality of life and that of its owner. Allergic skin disease is one of the most frequent reasons owners present their dog to a veterinarian.
"The licence extension demonstrates further innovation from Zoetis in the field of veterinary dermatology, and across the continuum of care, increasing the treatment options available to manage pruritus. Apoquel remains an ideal choice for short-term control due to its ability to provide rapid itch relief within four hours4 for as little as one day.5 This enables pruritus to be tightly controlled during the diagnostic work up,7 as well as being used for longer term control where tablets are the preferred method of administration.
"The sustained duration of action of Cytopoint makes it better suited to long-term management of pruritus, particularly when administering tablets is a challenge. Other benefits, such as no restrictions on age or with comorbidities, coupled with the flexibility of the new claim, make it a useful treatment at an earlier stage for more unique cases, e.g. young dogs or those with comorbidities."
For further information, contact your Zoetis Account Manager.
watch?v=A8EJ8LpLVzw&feature=youtu.be
References
The Government has announced that from 6 April 2016 all dogs will be required to have a microchip.
This will give owners 3 years to comply with new legislation being drafted by Defra.
According to Defra, 100,000 dogs are dumped or lost each year at a cost of £57 million to the taxpayer and welfare charities. Only 60% of the 8 million dogs in the UK are currently chipped.
Making microchipping compulsory is intended to help reunite owners with lost or stolen pets, relieve the burden on animal charities and local authorities and protect the welfare of dogs by promoting responsible dog ownership.
Owners will be able to get their dog microchipped free at any of the 18 Dogs Trust centres around the UK, and free microchips will be offered by Dogs Trust to local authorities, housing associations and veterinary surgeries. In addition Battersea Dogs and Cats Home has announced that free microchipping will be offered at its three centres, and the Blue Cross will also offer free microchipping to dogs and cats at its 16 hospitals and centres across England.
Veterinary associations have hailed the introduction of compulsory microchipping for all dogs in England as a giant leap forward for dogs and their owners. BVA President Peter Jones said: "The introduction of compulsory microchipping is a giant leap for dogs and their owners and is something that vets have long campaigned for. Microchipping is a safe and effective way to link dogs to their owners and is an essential part of responsible ownership."
The Government also announced plans to extend the scope of the Dangerous Dogs Act to private places and to allow police to decide if dogs seized under the Act can stay with their owners until the outcome of the court case, removing the need for these dogs to be kennelled. Both of these measures were supported by BVA and BSAVA in joint responses to the Defra consultation.
Virbac has launched the UK's first blood test for BPH (benign prostatic hyperplasia) which, according to the company, will provide practices with a significant opportunity to improve the prognosis for many of the UK's male dog population that suffer from the condition but go undetected.
Odelis CPSE is the first ELISA test to screen, diagnose and monitor BPH. Virbac Product Manager Chris Geddes MRCVS believes that the test is an important step forward in the diagnosis of the condition: "Not only does Odelis CPSE provide a simple and reliable alternative to rectal palpation, it will also give an objective measure of the degree of BPH present."
According to Chris, although BPH affects over 80% of entire male dogs over five years old, many go undiagnosed until the condition is advanced and symptoms become apparent. "Whilst regular screening is recommended in elderly dogs, rectal palpation is not a particularly popular process to carry out routinely without the presence of symptoms.
"We know that currently diagnosis of BPH falls well below the incidence, however this new test means that practitioners can now routinely monitor 'at-risk' dogs, e.g. stud males, elderly dogs, and those with a previous history of BPH. Bloods can be taken at practice visits, or routinely at vaccination boosters or annual health checks for example. So the test is not only good for animal welfare, it's a great business opportunity too".
There are three labs in the UK selected to carry out the test: Biobest; Carmichael Torrance; and Nationwide Laboratories.
Information is being mailed to all practices. Your first test free, and all positive test results recorded up to 31st October will receive a 'buy one get one free' promotion for Ypozane (osaterone acetate), the first-line treatment for BPH.
Alternatively, contact your local Virbac territory manager, or call Virbac on 01359 243243.
The RCVS Disciplinary Committee has severely reprimanded and warned as to his future conduct a veterinary surgeon who failed to make sufficient enquiries about the location or condition of a cat; unreasonably refused to provide it with first aid and pain relief; and failed to provide it with adequate 24-hour emergency care.
Following a three-day hearing, the Committee found Marcus Kutschera, of South London Emergency Veterinary Centre, Streatham, guilty of serious professional misconduct in relation to events on 16 May 2011. Mr Kutschera was Clinical Director of the practice, which provided out-of-hours emergency services to several London veterinary practices. At about 1.45am, the practice received two telephone calls from a representative of a registered charity about a cat, which the caller considered should be seen by a veterinary surgeon as soon as possible. The charity was itself a client of one of the practices whose out-of-hours emergency services were provided by the South London Emergency Veterinary Centre. The cat was later euthanased by the RSPCA.
After listening to a recording of a telephone call between a representative of the charity and Mr Kutschera, during which Mr Kutschera failed to ask about either the condition or location of the cat, the Committee was in no doubt that the caller believed Mr Kutschera would not see the cat unless he was able to pay when it was presented. The Committee said that, once the telephone call had been received, the primary responsibility of the veterinary surgeon was the welfare of the animal, and Mr Kutschera had no good reason not to see the cat or to follow the procedures set out in the Guide to Professional Conduct 2010. If he had made proper inquiries, he would have been able to make a provisional diagnosis that the cat was likely to be euthanased. Mr Kutschera was guilty of unreasonably refusing to provide first aid and/or pain relief to the animal, and of failing to provide adequate 24-hour emergency care.
The Committee concluded that Mr Kutschera's conduct fell far short of that to be expected of a veterinary surgeon. Although he did recommend that the cat should be taken to the RSPCA, his primary concern was the ability of the client to make a payment on presentation of the cat, and not the animal's welfare. He had a responsibility for ensuring that proper emergency cover was provided.
In mitigation, the Committee noted that the event was a single, short telephone call between Mr Kutschera and the client in the early hours of the morning, and there was no evidence to suggest similar behaviour on his part on other occasions. Mr Kutschera accepted that he made no inquiries into the cat's condition or location, and the Committee accepted that he had shown some insight into what went badly wrong. He said that he had subsequently changed his practice when speaking to clients on the telephone. The Committee also took account of the impact on Mr Kutschera of the case hanging over him since the complaint was made in August 2011 and, as the cost of the Disciplinary Committee inquiry was not covered by his professional indemnity insurance, he had taken on a substantial financial commitment to pay for legal representation.
Professor Peter Lees, chairing and speaking on behalf of the Committee said: "The primary purpose of the sanction is not to punish but to protect the welfare of animals, maintain public confidence in the profession and uphold proper standards of conduct. Whilst there are undoubted financial issues that can arise in the operation of an out-of-hours service, the primary responsibility of the veterinary surgeon is for the welfare of the animal."
The Committee recommended that Mr Kutschera undertake, within 12 months, continuing professional development training, with a particular emphasis on animal welfare, ethics and client care, in the context of providing out-of-hours services. It imposed on Mr Kutschera the sanction of a severe reprimand and a warning as to his future conduct.
In the week that Prince Charles has become embroiled in another row about the use of homeopathy in the NHS, British veterinary surgeons have denounced its use for the treatment of pets and other animals.
In a survey of veterinary surgeons carried out on this website, in which 460 members took part and the preliminary results of which are announced today, an overwhelming 83% said that there are no medical conditions for which homeopathy could be an effective treatment in animals. This figure included the 6.3% of participants who practice veterinary homeopathy themselves, without whom the figure would be even higher.
More specifically, when asked how they would best describe veterinary homeopathy, 4.5% said 'A reliably effective form of veterinary medicine', 8.7% said 'an occasionally effective form of veterinary medicine, 9.5% said: 'a rarely effective form of veterinary medicine, and 77.3% said: 'An ineffective form of veterinary medicine'.
The survey was carried with Alex Gough MA VetMB CertSAM CertVC PGCert MRCVS, Head of Medicine Referrals at Bath Veterinary Group.
So strongly did veterinary surgeons feel about the matter, 78.4% felt that their colleagues should not be allowed to practice homeopathy under their professional title of MRCVS. 73% said that whilst they are still allowed to do so, pet owners should be asked to sign a disclaimer that they understand that in trials, homeopathy has been shown to be ineffective.
However despite the almost universal denunciation of veterinary homeopathy within the profession, when it comes to directing their clients, it seems that many veterinary surgeons do not have quite the same courage of their convictions. Asked what would be the most appropriate response when asked by a client to refer an animal for homeopathic treatment, only 24% of vets said they would explain that homeopathy does not work and recommend the client does not self-refer for homeopathic treatment. 17.5% said they would explain that homeopathy does not work and advise the client to self-refer. 34% said that they would explain that homeopathy doesn't work and refer anyway, and 24% said they would just refer the case.
The survey follows the launch last year of a new feature on VetSurgeon Jobs and VetNurse Jobs which allows employers to highlight the salary and benefits they offer. Specifically, the system allows practices to display a 'minimum offer', described to the job seeker as the starting point for a discussion, or a salary range.
Still, currently only 10% of job adverts on VetSurgeon.org and 16% on VetNurse.co.uk include the salary, despite some evidence that broadly speaking, advertising a salary can improve response rates.
But do veterinary job seekers want to see the salary advertised, and if so, how much of a different could it make? These are questions this survey seeks to answer.
My guess is that it may be more important to veterinary nurses than veterinary surgeons, because there is probably a greater variability in salaries amongst nurses, and more jobs where you'd struggle to pay the mortgage.
It'll be interesting to see.
To take part in the survey, which is completely anonymous, visit: https://www.surveygizmo.com/s3/5110214/Should-veterinary-salaries-be-advertised. It's 4 quick fire questions which should take you less than a minute.
Davies says the new treatment is appropriate for dogs with severe diffuse elbow dysplasia, where cartilage wear results in bone rubbing against bone, called medial compartment disease (MCD). In these cases, Davies says that the prognosis is typically poor but now CUE is providing a promising alternative surgical option when arthroscopic and non-surgical options have failed.
The surgery involves partial resurfacing of the elbow joint. By focusing on the specific area of disease in the medial compartment, the CUE implant provides a less invasive bone-sparing option for resurfacing the bone-on-bone medial compartment while preserving the dog’s own good cartilage in the lateral compartment. Davies says that in most dogs, the technique significantly improves the pain and lameness that was caused by bone-on-bone grinding.
Unlike total elbow replacements, CUE does not require major bone cutting. On average, recovery tends to be significantly faster with progressive improvement peaking six months after surgery.
Mike Farrell, EBVS European and RCVS Specialist in Small Animal Surgery (Orthopaedics) at Davies recently performed a successful CUE procedure on Rubee, an 11-year-old Labradoodle diagnosed with severe MCD. At the recheck, six weeks after surgery Mike said: "Rubee’s early response to CUE has been nothing short of astonishing. I would have been pleased if she had made the improvement seen today after six months rather than six weeks."
Louise Clark Head of Anaesthesia and the Pain Clinic at Davies Veterinary Specialists continued: "CUE potentially provides a surgical alternative for what is currently an incredibly frustrating condition to manage and one that causes animals a lot of pain, and owners a great deal of angst.
"Arguably it is an ethically robust procedure because it can dramatically reduce patient pain with a relatively well defined risk of complications in a patient cohort that is otherwise at risk of euthanasia because of elbow disease."
For more information, visit: https://vetspecialists.co.uk/services/orthopaedics/
Eukanuba has published the results of a 10 year study to evaluate the health and longevity of continuously Eukanuba-fed dogs, in which 90% lived beyond the breed's typical lifespan.
Before the start of the study, a independent panel of veterinary academics and experts assessed existing evidence concerning the longevity of Labrador Retrievers and came to a consensual conclusion that the average lifespan for the breed is 12 years.
39 Labrador Retrievers in early to mid-adulthood were then enrolled in the study1, which began in 2004. All the dogs were neutered and had identical housing, standardised daily care and veterinary care. The dogs were fed the amount of food needed to maintain each dog within an optimal body condition score.
Remarkably, 28% of the dogs in the study achieved exceptional longevity, living beyond 15.6 years. One dog very nearly made it to 18 years of age.
The study was overseen Eukanuba's Longevity Council, a panel of international vet and industry experts including Professor Stuart Carmichael, Dr Penny Watson, Dr Vicki Adams, Professor Steve Dean and David Morgan, which collectively agreed that the secret to healthy ageing in canines is a careful balance of nutrition, good husbandry and effective veterinary care.
Professor Steve Dean, Former Chairman of the UK Kennel Club said: "Nutrition is a major contributor to the health of dogs in the long term, of course it isn’t the only contributor; good husbandry and good veterinary care are the other major pillars for health and longevity. The correct nutrition has a big part to play in maintaining dog health throughout its entire life, which we’ve found out from the Eukanuba Long Life Observation, can be a lot longer than we have previously expected. We’ve always assumed that Labradors will live 12 years if we’re lucky, but now we have a whole new target to aim for…16 and 17 years. It is quite phenomenal."
Dr Penny Watson, Senior Lecturer in Small Animal Medicine, Queen’s Veterinary School Hospital, University of Cambridge said: "Vets as a profession are very good at treating diseases in animals, but perhaps slightly less good at giving preventative advice to pet owners about healthy lifestyles. As vets, we should be thinking all through an animals life cycle, from puppy to geriatric, about the preventative aspects, such as good diet, maintaining the right body condition score and other aspects including dental care, rather than just looking disease and treating it."
David Morgan, Eukanuba’s Senior Scientific Communications Manager said: "The hope is that we can take the message that it’s not only about nutrition but what we call appropriate care, which is veterinary care and husbandry, looking after the dogs in a responsible way. Because, yes we have some great observations and we are starting now with Dr Vicki Adams to break down into more detail what we’ve actually seen in the Eukanuba Labradors and what recommendations we can give in the future so that all dogs can have that longer, healthy and more vibrant lives."
Reference
Buprelieve is a 0.3mg/ml buprenorphine solution for injection, licensed for post-operative analgesia and to potentiate the sedative effects of other centrally-acting agents in dogs and horses. It can be administered by intramuscular or intravenous injection to dogs and cats and by intravenous injection to horses and is available in 10ml multi-dose glass vials.
Dr Rich Irvine BVSc MRCVS, veterinary services manager at Jurox (UK) Limited said: "We are delighted to be extending our range of products with the launch of Buprelieve which will provide veterinary practices with effective and economical analgesia.
"The launch of Buprelieve will be supported by our highly qualified team of veterinary surgeons who aim to deliver top quality help, advice and assistance for clinics wishing to perform best practice anaesthesia across all patient groups."
Jurox says it has been listening to the concerns of veterinary surgeons who say they want high quality generic medicines at affordable prices along with transparency as to what they are paying for each vial. As a result, the company says it is launching Buprelieve at a very affordable list price with a simple and generous introductory offer or rebate.
Richard Beckwith, country manager of Jurox (UK) Ltd, said: "Jurox prides itself on providing customers with a range of high quality medicines and we believe the launch of Buprelieve will also satisfy vets’ increasing requests for competitively priced products. We understand that providing high quality pain relief is critical and Buprelieve helps vets deliver the care they demand for their patients."
For more information, contact your local Jurox technical advisor, telephone the customer services team on 0800 500 3171 or e-mail: info@jurox.co.uk.
A test by the Australian Racing Forensic Laboratory (ARFL) of samples from a newly prepared batch of Bova’s 100mg/ml injectable omeprazole formulation did not detect testosterone, and Racing New South Wales has now released a statement that the product can continue to be used in racehorses following the guidance of Australian Commonwealth and State legislation.
Nick Bova, managing director of Bova UK, said: "Traces of testosterone in the previous batch were less than one millionth of the internationally accepted standard for impurities.
"Independent experts confirmed that there could be no adverse effects on equine health or equestrian sport, however, we have taken steps to identify and completely eliminate the excipient ingredient that contained traces of testosterone."
Nick added: "Bova can confirm that new batches of this product will not contain the previous trace levels of testosterone and therefore Bova are confident there will be no antidoping issues, no matter what the equestrian pursuit is."
Dr Berwyn Clarke, CEO of PBD Biotech, which developed the bacteriophage-based detection method, says this is significant step forward: "In situations where a farm has had an ongoing chronic bovine TB problem, APHA’s protocol offers a promising new approach to controlling the infection.
"Actiphage is now included within a series of measures that farmers can use in conjunction with their vet and with specific APHA approval as a means to improving their disease management strategy.
"For many farms that have been struggling for years it provides the first step to becoming TB free. This move by the APHA is a really positive step towards tackling this devastating disease."
Much of this new strategy, as part of a private TB eradication plan, has been driven by the success of Devon-based vet Dick Sibley, who incorporated Actiphage into a disease management strategy last Autumn to help clear a dairy herd that had been stricken with TB since 2012.
Dick said: "The approach of directly measuring the presence of live bacteria in the blood in just six hours is a totally different but complementary measurement to other technologies and has enabled enhanced testing, early detection and containment of the infected animals.
"We don’t have all of the answers yet, but it’s about predicting, preventing and managing what we can – and Actiphage has contributed greatly to the outcome we’ve been after for so long."
The Exceptional private use of non-validated tests for TB on cattle in England protocol enables any private veterinary surgeon to request APHA permission for exceptional use of Actiphage and the other non-validated tests, subject to certain criteria that include herd supplementary interferon-γ (IFN- γ) testing, discussions with the APHA Case Vet and the farmer’s written consent.
Berwyn added: "Actiphage is unique in directly detecting live mycobacteria in blood or milk, and it can also distinguish between a vaccinated and an infected animal - paving the way for new types of disease control when vaccines become available in the future.
"We are working with international governments, and the test is being trialled on bovine, ovine as well as exotic species, but we appreciate it is new to the UK market so we’re keen to answer any queries vets or farmers may have."
The new test will be profiled in the Innovation Hub at the Royal Norfolk Agricultural Show next month (27 & 28 June).
PBD Biotech says Actiphage will require further testing before it is officially approved for standard veterinary use in the UK, however under the APHA protocol it is now permitted for private use where herds have experienced persistent breakdowns and this will contribute to the evidence-base required for official validation by the OIE and acceptance by APHA.
Within this protocol, APHA has outlined a number of other non-validated tests that may be proposed for exceptional use in cattle herds with chronic breakdowns, including: the Actiphage assay, developed by PBD Biotech and Nottingham University; the Enferplex TB serological test, produced by Enfer Laboratories Ireland and approved in GB for use in camelids; and the Polymerase Chain Reaction (PCR) testing of faecal samples. APHA says this is not an exhaustive list and that the protocol covers any current or future non-validated tests for bovine TB.
The comparative intradermal tuberculin skin test and the IFN- γ blood test remain the only ante mortem tests currently approved for the statutory cattle TB testing programme in Great Britain.
The full Exceptional private use of non-validated tests for TB on cattle in England is available on the APHA Vet Gateway: apha.defra.gov.uk/vet-gateway/non-valid-tb-testing
The announcement came in the form of a written statement by the then Home Secretary Sajid Javid to the House of Commons on 23rd July, which said: "The Government is happy to accept all of the MAC’s recommendations on the composition of the SOL and the necessary amendments will be made in the Autumn Immigration Rules changes."
Being on the shortage occupation list means that employers do not need to advertise jobs for veterinary surgeons in the UK for 28 days before advertising abroad (the Resident Labour Market Test). In addition, there are lower visa fees and it provides exemption from the minimum income threshold.
RCVS President Niall Connell said: "Both the Royal College of Veterinary Surgeons and the British Veterinary Association worked together to ensure this outcome, which will see a lowering of the immigration barriers, for example, in terms of visa requirements, for overseas veterinary surgeons who wish to live and work in the UK.
"We also considered this a vital piece of preparation for the UK leaving the EU, as around half of those registering as veterinary surgeons with the RCVS in a given year are non-UK EU nationals and we would not want to see this vital supply of veterinary talent immediately dry up should ‘freedom of movement’ end when the UK leaves the EU.
"We thank Mr Javid for accepting the Committee’s proposals and congratulate his successor Priti Patel on her appointment and look forward to the decision being implemented. The new Prime Minister pledged on the steps of Downing Street to do more to promote the welfare of animals, and having veterinary surgeons on the Shortage Occupation List will help in our mission to uphold animal health and welfare and ensure that vital veterinary work can continue to get done, whatever happens with the relationship between the UK and the EU."
The buy-out was led by Professor Nick Bacon, Clinical Director, Dr Laurent Findji, Senior Clinician, Dr Jonathan Bray and Dr Gerard McLauchlan, who will collectively take the hospital forward with the financial backing of a small team of external investors.
Professor Noel Fitzpatrick will continue to lead Fitzpatrick Referrals Orthopaedics and Neurology and Fitzpatrick Referrals Institute for the Restoration of Skeletal Tissue which are both based in Eashing, Surrey.
Fitzpatrick Referrals Oncology and Soft Tissue is rebranding as AURA Veterinary, continuing to focus on animal oncology, soft tissue surgery, interventional radiology and internal medicine.
Under the new management team, AURA Veterinary says it has plans to invest in its team, equipment, scientific innovation and research.
Noel said: “I am proud of everything and everyone who has been part of the journey over the last seven years.
"It is a world-class hospital with an unrivalled team and the foundation we have built together is incredible.
"The time is now right for the team to embark on the next part of their journey - allowing me to also go forward and focus my passion, energy and time at Fitzpatrick Referrals Orthopaedics and Neurology and lead that team into its exciting new phase.”
Nick Bacon, Clinical Director, said: “It was a wonderful opportunity to be involved with a hospital like this from the very beginning, and it’s exciting to be part of its new chapter.
"Laurent and I are hugely grateful to Noel for his vision in creating the hospital, which is unparalleled in the level of care, skill and innovation our team can provide for our patients.
"We look forward to the growth and success of AURA Veterinary.”
Photo: Dr Gerard McLauchlan (standing, back left, in darker scrubs), Professor Nick Bacon, Clinical Director (sitting, front left), Dr Jonathan Bray, (sitting, right), Dr Laurent Findji, Senior Clinician (standing, far right)
Davies says its Cardiac Electrophysiology Laboratory, headed by Pedro Oliveira (pictured right), is one of only four centres in the world to perform the procedure, and it has usually required human medical support. The fact that they've been able to operate independently means the procedure should now start to become more readily available.
The procedure involves introducing special catheters via peripheral veins into the heart, where they are used to record the electrical activity of the heart muscle, thereby allowing the identification of the source and mechanism of cardiac arrhythmias.
Once the abnormal tissue is found, it is destroyed using intense localised energy delivered by another specialised catheter: radiocatheter ablation.
This technique is common in human medicine but very rare in veterinary medicine because of the level of specialisation needed.
In the past, the cardiology team at Davies needed the support of a consultant and a cardiac physiologist from the human field to help carry out the surgery. Having now done it unaided, Pedro is confident that in time Davies will be able to help considerably more patients, promptly after diagnosis.
Pedro said: "In three years we have treated one cat and 19 dogs. Several cases did not survive long enough for surgery despite a waiting time of only a few days to up to two weeks from referral to the procedure. Most of these dogs were puppies. This is incredibly frustrating as if performed early these procedures are curative for most patients."
Davies says that to date it has had a procedural success rate of 100%, with recurrence of the arrhythmia in just one dog. The remaining dogs were cured from their arrhythmias and recovered fully except for two dogs that had sustained too much heart muscle damage and continued to suffer from congestive heart failure.
Pedro added: "Hopefully in the future severe muscle damage can be avoided by early referral when the arrhythmia is detected. If you diagnose a cardiac arrhythmia, especially supraventricular tachycardia, please consider this treatment option because it is very likely to be curative."
The Davies cardiology team can be contacted at cardiology@vetspecialists.co.uk.
Incidentally, Pedro has also co-authored (with Ruth Willis and Antonia Mavropoulou) a new book on electrocardiography. Guide to Canine and Feline Electrocardiography will be published in September 2018 and is available for pre-order on Amazon now, priced at £89.99.
The main aim of the campaign is to persuade anyone thinking of getting a puppy that they should always see the animal at least once whilst it is still dependent on its mother, before they buy. That way, they'll be able to reassure themselves that they have seen the real bitch and the environment in which the puppy was bred. It will also help prevent impulse purchases.
In addition, the campaign aims to raise awareness in the veterinary profession, so that veterinary surgeons are giving this same advice to their clients.
To that end, the campaign highlights the RSPCA 'Sold a pup' report which showed that over 400,000 pups are bred for the UK market each year by unlicensed establishments, and imports from Europe have increased to an estimated 30,000 in 2015, following the change in the PETS scheme in 2012.
The campaigners say that many of these puppies are bred in truly awful conditions, often with little or no human contact, before being taken taken from their mothers too early and transported often hundreds or thousands of miles to be sold as 'family' pets. Many will need veterinary care to deal with infections, inherited issues and behavioural problems.
The campaign faces a big challenge. In the Kennel Club PAW survey 2014, 41% of people who bought a puppy didn't see the bitch and 51% didn't see the environment where the litter was bred.
To spread the word, veterinary surgeons, veterinary nurses and pet owners are being asked to take a pouting selfie with their dog and post it on social networks like Facebook, with the hashtags #PoutForPuppies #SeeThemSuckling, linking to the campaign website: https://seethemsuckling.com
Fynadyne had been removed from sale last year after the Veterinary Medicines Directorate suspended the sale of any medicinal products containing the excipient diethanolamine (DEA), following advice to the European Medicines Agency that it could pose a risk to human health.
Finadyne 50mg/ml Solution for Injection is indicated for the alleviation of acute inflammation and pain in both cattle and pigs. It is also indicated for the alleviation of inflammation and pain associated with musculo-skeletal disorders and colic in horses.
The reformulated product has a shelf life of three years and is now available from wholesalers in 50ml and 100ml vials.
For further information, contact your MSD Animal Health account manager.
Nat Whitley, clinical director at Davies Veterinary Services, said: "We are delighted to become part of the Linnaeus Group. We pride ourselves on delivering excellent service, so when the opportunity arose to become part of such a forward-thinking, impressive group it was a great match."
Emma Barnes, Linnaeus Group operations director, said: "We are very pleased to welcome Davies Veterinary Specialists to the Linnaeus family and look forward to combining their excellent work and care with our expertise, experience and support.
"We carefully select our partners in the Group to ensure the delivery of the highest quality of care and service across the entire business, which is why we are so pleased to have the Davies team on board."
Mr Wood was removed from the Register in 2018 after being convicted of posessing indecent images of children and made subject to a Sexual Harm Prevention Order for five years.
Mr Wood first applied to rejoin the Register in 2020 but his application was rejected.
At the outset of his second application last month, Mr Wood’s counsel argued that he is professionally competent to be restored, that he had strong mitigation for his offending, that he had consistently and repeatedly expressed and demonstrated profound remorse, that he posed a low risk of re-offending, that he had proactively engaged with the Probation Service and voluntary counselling to gain further insight into his offending, and that he had completed his community sentence and was no longer subject to any of the court orders arising from his conviction.
The Committee then weighed up whether Mr Wood had accepted its original findings in 2018, the seriousness of the offences, whether he demonstrated insight, protection of the public and the public interest, the future welfare of animals should he be restored to the Register, the length of time off the Register, Mr Wood's conduct since he was removed and evidence that he had kept up-to-date with veterinary knowledge, skills and practice.
Dr Kathryn Peaty MRCVS, chairing the Committee and speaking on its behalf, said: “The Committee is satisfied that Mr Wood has done everything required of him in order to be able to satisfy the Committee that he is fit to be restored to the Register.
“At the last application in June 2020, he was unsuccessful largely because of the outstanding ancillary Court Orders that did not conclude until early 2023. Those Orders have now concluded
“He has shown significant insight into his offending behaviour. He has been proactive in his rehabilitation and taken significant steps to ensure there would be no repetition.
“He has a small, but strong, network of people around him who appear to genuinely care about him and support him. He has worked hard at maintaining his skills and knowledge, in so far as he has been able to in light of not being able to practise as a veterinary surgeon.
“He is thoughtful and realistic about his prospects going forward. His responses to questions about addiction were appropriate and persuasive. He has expressed genuine remorse and there is, in the Committee’s view, a public interest in allowing him to be restored to the Register.”
www.rcvs.org.uk/disciplinary
According to the charity, FIP, which is one of a number of chronic viral infections of cats that resemble those in people, is estimated to kill up to 1.4% of cats around the world.
The infectious agent is a mutant coronavirus (FIPV) that is notoriously difficult to control: the parent enteric coronavirus is present in virtually all catteries and shelters and is shed by 60% or more of pet cats from multi-cat households,1 and vaccines are ineffective.
Among the most promising treatments against emerging viruses in humans is 'GS-5734', one of the small-molecule antivirals targeting specific proteins involved in RNA virus replication.
In studies, it has proven effective in preventing Ebola in rhesus monkeys and inhibiting coronaviruses both in tissue culture and in mouse infection models.
It was these findings that brought it to the attention of a team of veterinary researchers in the USA, led by Professor Niels Pedersen of the University of California, Davis.
Their own initial studies involving experimental FIP showed that the less chemically complex 'GS-441524', the parent nucleoside of GS-5734, was highly effective, opening the way for a field trial in cats with naturally occurring FIP, the results of which are published in this week's JFMS2.
Thirty-one cats, ranging in age from 3–73 months, were enrolled in the study, and 26 completed the planned 12 weeks or more of treatment; the remainder died or were euthanised due to their severe disease.
For these 26 cats, the clinical response was dramatic: fever usually resolved within 12–36 h, concurrent with a marked improvement in appetite, activity levels and weight gain.
In cats with the more common effusive or ‘wet’ form of FIP, abdominal effusions rapidly disappeared, starting at around 10–14 days after commencing treatment.
Encouragingly, and somewhat unexpectedly, cats with non-effusive (‘dry’) FIP and older cats responded as well to GS-441524 treatment as did cats with effusive FIP and young cats. The safety profile of GS-441524 was likewise impressive.
Currently, 24 of the 26 cats remain healthy, with one having succumbed to FIP disease and one to unrelated heart disease. Eighteen of these cats underwent just one round of treatment; the remaining eight suffered disease relapses, but these were successfully treated with a further (in two cases, a third) round of treatment at a higher dose.
Previously the prospects for cats with FIP were bleak. In a review paper on FIP published in JFMS a decade ago, Professor Pedersen stated: "no treatment has proven effective in curing cats of FIP, in spite of the claims. Cats that develop FIP inevitably die of their disease in days, weeks or months."1
Now, as he approaches the end of his professional career, Professor Pedersen is considerably more optimistic: "FIP has been my fascination for the past 50 years and I am fortunate to have reached a final stage in my career having identified safe and effective antiviral drugs. We now know that small molecules targeting specific steps in RNA virus replication are capable of safely curing various forms of FIP."
However, he cautioned: "It must be emphasised that the field trial we report was for proof-of-concept and the results cannot be immediately translated into commercially available products.
"Unfortunately, the real hope provided by these initial trials has increased, and not decreased, the desperation of owners to seek out these new drugs on the black market. As eventful as these discoveries may be, there is still much more about FIP to discover.
"I would like to thank all of the people, organizations and owners who have assisted in my research over this half century and leave remaining questions and associated discoveries for my fellow FIP researchers."
Photo: Bubba, one of the study cats, in recovery. Courtesy Adel Gastle
Credelio Plus is a palatable, chewy, monthly tablet which contains milbemycin oxime for the control of the gastrointestinal nematodes: hookworm (L4, immature adult (L5) and adult Ancylostoma caninum), roundworms (L4, immature adult (L5) and adult Toxocara canis and adult Toxascaris leonina) and whipworm (adult Trichuris vulpis). Also for the prevention of angiostrongylosis by reduction of the level of infection with immature adult (L5) and adult stages of Angiostrongylus vasorum (lungworm) with monthly administration. Also for the prevention of heartworm disease (Dirofilaria immitis).
Credelio Plus also contains lotilaner for the immediate and persistent treatment of ticks (Dermacentor reticulatus, Ixodes ricinus, Rhipicephalus sanguineus and I. hexagonus) and flea (Ctenocephalides felis and C. canis) infestations in dogs.
Credelio Plus is licensed for puppies as young as 8 weeks and weighing 1.4 kg or more.
Tina Hunt, General Manager of Elanco UK/Ireland said: "The launch of Credelio Plus represents another exciting evolutionary leap for Elanco’s parasiticide portfolio.”
Cat Henstridge MRCVS, otherwise known as 'Cat the Vet' said: "As a companion animal vet, one of the common challenges I see from pet owners is the need to remember and administer multiple treatments to cover a variety of parasites.
"So a simple, easy-to-remember treatment will be welcomed by my clients who need a combination solution to protect their dogs from ticks, fleas and worms.”
To mark the launch of Credelio Plus, Elanco is inviting vets and nurses to register for an online event at which the astronaut Major Tim Peake will talk about the lessons he’s learnt about leadership and teamwork, performing in high-pressured environments and the future of medicine and science. He'll be followed by Cat Henstridge, who will give a presentation about the power of wider veterinary teams working ‘better together’ to support each other, and how practices can start to reconnect with their clients following lockdown.
Lepha McCartan, BVetMed MRCVS, Veterinary Technical Consultant, Elanco Animal Health, will also speak about Elanco’s ongoing work within the parasite space. There will also be a live Q&A where attendees can put questions to the panel.
To sign up for the launch event, visit https://www.myelanco.co.uk/brand/credelio-plus-launch-registration